News | August 01, 2025
Jubilant Ingrevia Q1 FY26 YoY net profit jumps 54% to Rs. 75 Cr
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
NewCo’s pipeline includes five investigational medicines
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
This year, the OCTF focused on preparing a white paper on oral cancer elimination in India and updating its annual consensus guidelines
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
The company reported consolidated EBITDA loss of Rs. 10.5 crore in Q1 FY26 as compared to loss of Rs. 45.3 crore in the same period last year
The latest BioE3 policy builds the framework for high-performance biomanufacturing to propel the development and production
Revenue increased 11.4 per cent to Rs. 8,545 crore
This partnership aims to address the growing demand for high-quality diagnostics in metropolitan areas
Subscribe To Our Newsletter & Stay Updated
